文献速递糖尿病

2-6岁儿童自动胰岛素输送的有效性与安全性(LENNY):一项开放标签、多中心、随机交叉试验

Efficacy and safety of automated insulin delivery in children aged 2-6 years (LENNY): an open-label, multicentre, randomised, crossover trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2025-06-19

LENNY试验在芬兰、意大利、斯洛文尼亚和英国的12家医院纳入2-6岁1型糖尿病儿童,比较MiniMed 780G系统自动模式与手动模式联合低血糖前暂停功能(手动+SBL)的疗效与安全性。主要终点TIR在自动模式为68.3%,手动+SBL模式为58.3%,调整后组间差异9.9个百分点(95%CI 8.0-11.7),达到非劣效且自动模式优效。

要点

  • 自动模式TIR为68.3%,手动+SBL模式为58.3%,调整后差异9.9个百分点(95%CI 8.0-11.7),自动模式优效。
  • 自动模式HbA1c为7.00%,手动+SBL模式为7.61%,调整后差异-0.61个百分点(95%CI -0.76至-0.46),自动模式优效。
  • 严重不良事件共9例,均判定与设备或操作无关;自动模式期间报告1例糖尿病酮症酸中毒严重不良事件,未报告严重低血糖事件。

核心结论

  • 在2-6岁1型糖尿病儿童中,MiniMed 780G系统自动模式的TIR非劣于手动+SBL模式,且TIR和HbA1c的改善支持自动模式。
  • 自动模式观察到的安全性特征可接受。

研究设计与样本

  • 开放标签、多中心、随机交叉试验,纳入芬兰、意大利、斯洛文尼亚和英国12家医院的2-6岁1型糖尿病儿童,每日胰岛素需要量至少6单位。
  • 参与者先进行2周导入期,使用MiniMed 780G系统手动模式并启用低血糖前暂停功能(手动+SBL),随后进入26周研究阶段。
  • 研究阶段随机分配至自动模式12周、洗脱2周、手动+SBL模式12周的序列(AM-MM序列),或相反顺序序列(MM-AM)。
  • 98名参与者开始研究阶段(AM-MM组n=50,研究期间2例退出;MM-AM组n=48);总体平均年龄4.7岁(SD 1.2),女性48/98(49%),男性50/98(51%)。
  • 主要终点为自动模式与手动+SBL模式之间TIR(70-180 mg/dL)百分比的组间差异,以最小二乘均值差表示,校正序列效应和导入期TIR,非劣效界值7.5个百分点;主要和次要分析均按意向治疗进行。

主要发现

  • 平均TIR在导入期为58.1%(SD 14.3),自动模式为68.3%(SD 6.9),手动+SBL模式为58.3%(SD 12.5);调整后组间差异9.9个百分点(95%CI 8.0至11.7),主要终点达到非劣效且自动模式优效。
  • 平均HbA1c在导入期为7.53%(SD 0.96;58.8 mmol/mol [SD 10.5]),自动模式为7.00%(SD 0.53;53.0 mmol/mol [SD 5.8]),手动+SBL模式为7.61%(SD 0.91;59.7 mmol/mol [SD 9.9]);组间差异-0.61个百分点(95%CI -0.76至-0.46),达到非劣效且自动模式优效。
  • 共报告9例严重不良事件(自动模式期间5例,手动+SBL模式期间2例,导入期1例,洗脱期1例),均判定与研究设备或操作无关;自动模式期间报告1例糖尿病酮症酸中毒严重不良事件;未报告严重低血糖事件。

临床怎么用

  • 作者认为,自动模式下TIR和HbA1c的显著改善可能有助于预防糖尿病相关并发症。
  • 作者认为,自动模式观察到的安全性特征可接受。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early-life glycaemic control disturbances can negatively affect brain development and plasticity. This study aimed to assess the efficacy and safety of automated insulin delivery (AID) with the MiniMed 780G system in children with type 1 diabetes aged 2-6 years requiring at least 6 units of insulin a day. METHODS: In this open-label, randomised crossover trial, we enrolled children from 12 hospitals in Finland, Italy, Slovenia, and the UK. Participants underwent a 2-week run-in phase in which the MiniMed 780G system was used in manual mode with the suspend before low feature enabled (manual+SBL), followed by a 26-week study phase. For the study phase, participants were randomly assigned to a sequence comprising a 12-week auto mode, 2-week washout, and 12-week manual+SBL mode (AM-MM sequence), or the reverse order sequence (MM-AM). The primary endpoint was the between-treatment difference for auto mode versus manual+SBL mode in the percentage of time in range (TIR, 70-180 mg/dL), expressed as the least-squares mean difference adjusted for sequence effect and run-in TIR, and assessed for non-inferiority (margin 7·5 percentage points). Secondary endpoints were the adjusted between-treatment difference in mean HbA1c at the end of each 12-week period assessed for non-inferiority (margin 0·4 percentage points), and the adjusted between-treatment difference in mean TIR and HbA1c assessed for superiority. The primary and secondary analyses were by intention to treat. Safety was assessed in all participants who signed informed consent. The trial was registered with ClinicalTrials.gov, NCT05574062, and is completed. FINDINGS: Recruitment took place from March 24 to Sept 21, 2023. 98 participants began the study phase (AM-MM: n=50, with two withdrawals during the study phase; MM-AM: n=48). Overall mean age was 4·7 years (SD 1·2); 48 (49%) of 98 participants were female and 50 (51%) were male. Mean TIR was 58·1% (SD 14·3) in the run-in phase, 68·3% (6·9) in auto mode, and 58·3% (12·5) in manual+SBL mode (adjusted between-treatment difference 9·9 percentage points [95% CI 8·0 to 11·7]; non-inferiority met for the primary endpoint with superiority for auto mode). Mean HbA1c was 7·53% (SD 0·96; 58·8 mmol/mol [SD 10·5]) in the run-in phase, 7·00% (0·53; 53·0 mmol/mol [5·8]) in auto mode, and 7·61% (0·91; 59·7 mmol/mol [9·9]) in manual+SBL mode (between-treatment difference: -0·61 percentage points [95% CI -0·76 to -0·46; non-inferiority met with superiority for auto mode). There were nine serious adverse events (five during auto mode, two during manual+SBL mode, one during run-in, and one during washout; all deemed to be unrelated to the study device or procedure), including one serious adverse event of diabetic ketoacidosis during auto mode. No severe hypoglycaemia events were reported. INTERPRETATION: In children aged 2-6 years with type 1 diabetes, the TIR with the MiniMed 780G system in auto mode was non-inferior to that in manual+SBL mode. The significantly improved TIR and HbA1c in favour of auto mode could help prevent diabetes-related complications. Additionally, the observed safety profile in auto mode was acceptable. FUNDING: Medtronic.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Battelino T, Kuusela S, Shetty A, et al. Efficacy and safety of automated insulin delivery in children aged 2-6 years (LENNY): an open-label, multicentre, randomised, crossover trial. Lancet Diabetes Endocrinol. 2025. PMID: 40544853. doi:10.1016/S2213-8587(25)00091-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。